Loading…
Employees: 735
Size Jiangsu Aidea Pharmaceutical (688488.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $743M, the 2935th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥11.77 on 6 Nov 2026.
Performance Over six months the shares fell 31.8%, against -15.8% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 7.1% over the last twelve months (peer median +3.9%); the operating margin is 7.9% (peer median 12.9%).
Valuation It trades at 123.9× forward earnings against a peer median of 12.2× (2nd most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points below its cost of capital (8.8% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥717M | CN¥711M | CN¥412M | CN¥409M | CN¥244M |
| Revenue growth | — | +73% | +1% | +68% | — |
| Gross profit | CN¥514M | CN¥453M | CN¥198M | CN¥158M | CN¥78.4M |
| EBITDA | n/a | CN¥89.6M | -CN¥94.9M | -CN¥58.3M | -CN¥130M |
| Net income | CN¥7.12M | -CN¥19.5M | -CN¥141M | -CN¥76.1M | -CN¥124M |
| Free cash flow | CN¥1.50M | -CN¥28.8M | -CN¥77.9M | -CN¥230M | -CN¥224M |
| Capital expenditure | CN¥67.6M | CN¥47.9M | CN¥44.6M | CN¥71.2M | CN¥140M |
| Total debt | CN¥698M | CN¥576M | CN¥521M | CN¥418M | CN¥221M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688488.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.5% | -5.5% | 2nd lowest of 20 |
| 6-month return | -31.8% | -15.8% | 4th lowest of 20 |
| Distance from 52-week high | -47.8% | -39.4% | 9th lowest of 20 |
| Revenue growth (TTM) | +7.1% | +3.9% | 8th highest of 19 |
| Operating margin | 7.9% | 12.9% | 7th lowest of 18 |
| Forward P/E | 123.9× | 12.2× | 2nd most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 33.8% | -1.1% | 2nd most demanding of 12 |
| Growth delivered (Del g) | +19.8% | +10.1% | 4th highest of 12 |
| Hurdle (Req g minus delivered) | +14.0 pp | -1.4 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | -2.7 pp | +2.3 pp | 7th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $743M | -32% | +7% | 8% | 123.9× | 33.8% | +19.8% |
| Rigel Pharmaceuticals RIGL | United States | $741M | +52% | +3% | 31% | 11.9× | -1.1% | +22.1% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $753M | -11% | +4% | 2% | n/a | 4.9% | +5.3% |
| Cullinan Therapeutics CGEM | United States | $728M | -22% | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $725M | +4% | +26% | 61% | 3.3× | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $724M | -16% | +1,079% | 81% | n/a | n/a | n/a |
| Ardelyx ARDX | United States | $724M | -58% | +18% | -8% | 225.1× | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $716M | -24% | +5% | -30% | 64.3× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | n/a | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 12.4× | -6.3% | +10.6% |
| Yabao Pharmaceutical 600351.SS | China | $711M | -3% | -3% | 16% | n/a | -7.5% | -2.8% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 28.8× | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 11.9× | 11.5% | +11.3% |
| Hainan Haiyao 000566.SZ | China | $710M | -19% | -18% | -50% | n/a | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $705M | -29% | -82% | n/a | 6.3× | 10.5% | -25.1% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | n/a | -1.4% | 0.0% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 3.4× | -7.0% | +20.3% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 17.8× | -1.1% | +26.1% |
| Bliss GVS Pharma BLISSGVS.NS | India | $698M | +126% | +21% | 15% | n/a | 37.0% | +10.1% |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | n/a | 0.2% | +0.5% |